Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation - PubMed (original) (raw)

Review

Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation

Andrew Leask. Circ Res. 2010.

Abstract

Fibrosis is one of the largest groups of diseases for which there is no therapy but is believed to occur because of a persistent tissue repair program. During connective tissue repair, "activated" fibroblasts migrate into the wound area, where they synthesize and remodel newly created extracellular matrix. The specialized type of fibroblast responsible for this action is the alpha-smooth muscle actin (alpha-SMA)-expressing myofibroblast. Abnormal persistence of the myofibroblast is a hallmark of fibrotic diseases. Proteins such as transforming growth factor (TGF)beta, endothelin-1, angiotensin II (Ang II), connective tissue growth factor (CCN2/CTGF), and platelet-derived growth factor (PDGF) appear to act in a network that contributes to myofibroblast differentiation and persistence. Drugs targeting these proteins are currently under consideration as antifibrotic treatments. This review summarizes recent observations concerning the contribution of TGFbeta, endothelin-1, Ang II, CCN2, and PDGF and to fibroblast activation in tissue repair and fibrosis and the potential utility of agents blocking these proteins in affecting the outcome of cardiac fibrosis.

PubMed Disclaimer

Cited by

Disruption of Osteoprotegerin has complex effects on medial destruction and adventitial fibrosis during mouse abdominal aortic aneurysm formation.
Bumdelger B, Otani M, Karasaki K, Sakai C, Ishida M, Kokubo H, Yoshizumi M. Bumdelger B, et al. PLoS One. 2020 Jul 2;15(7):e0235553. doi: 10.1371/journal.pone.0235553. eCollection 2020. PLoS One. 2020. PMID: 32614927 Free PMC article.
Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells.
Chrisochoidou Y, Roy R, Farahmand P, Gonzalez G, Doig J, Krasny L, Rimmer EF, Willis AE, MacFarlane M, Huang PH, Carragher NO, Munro AF, Murphy DJ, Veselkov K, Seckl MJ, Moffatt MF, Cookson WOC, Pardo OE. Chrisochoidou Y, et al. Cell Death Dis. 2023 Nov 8;14(11):725. doi: 10.1038/s41419-023-06240-x. Cell Death Dis. 2023. PMID: 37938546 Free PMC article.
Functional Gene Module-Based Identification of Phillyrin as an Anticardiac Fibrosis Agent.
Wang L, Zhang W, Lu Z, Wang B, Li Y, Yang J, Li P, Zhao M. Wang L, et al. Front Pharmacol. 2020 Jul 17;11:1077. doi: 10.3389/fphar.2020.01077. eCollection 2020. Front Pharmacol. 2020. PMID: 32765276 Free PMC article.
The pathogenesis of cardiac fibrosis.
Kong P, Christia P, Frangogiannis NG. Kong P, et al. Cell Mol Life Sci. 2014 Feb;71(4):549-74. doi: 10.1007/s00018-013-1349-6. Epub 2013 May 7. Cell Mol Life Sci. 2014. PMID: 23649149 Free PMC article. Review.
Profibrotic up-regulation of glucose transporter 1 by TGF-β involves activation of MEK and mammalian target of rapamycin complex 2 pathways.
Andrianifahanana M, Hernandez DM, Yin X, Kang JH, Jung MY, Wang Y, Yi ES, Roden AC, Limper AH, Leof EB. Andrianifahanana M, et al. FASEB J. 2016 Nov;30(11):3733-3744. doi: 10.1096/fj.201600428R. Epub 2016 Aug 1. FASEB J. 2016. PMID: 27480571 Free PMC article.

Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation - PubMed (original) (raw)